CSI Market
Sign In | Register

Baudax Bio Inc (BXRX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BXRX Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Baudax Bio Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income2.10
Depreciation & amortization0.14
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset-0.04
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.01
Share-based Compensation0.64
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants1.48
Increase Decrease In Right Of Use Asset-
Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities4.75
Noncash Or Part Noncash Acquisition Fixed Assets Acquired-
Loss On Impairment Of Construction In Progress-
Non Cash Interest Expense0.30
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.40
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.87
Discontinued operations-19.52
Net Cash flow from Operating Activities-9.68
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.00
Payments to Acquire Short-term Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Acquisition Of License Agreement-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale and Maturity of Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.14
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.12
Financing Activities
Short-term debt Net0.31
Other borrowing transactions-0.29
Long-term debt - borrowings0.00
Long-term debt - repayments-4.05
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock7.82
Proceeds from Contributions from Parent0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Equity Facility Net Of Transaction Costs-
Proceeds From Registered Direct Offerings Net Of Transaction Costs1.71
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities5.51
Effect of exchange rate on cash flow0.00
Discontinued operations-0.84
Free Cash Flow-9.70
Total Cash Flow-4.05
4 historic quarters locked

Sign in to unlock the full Baudax Bio Inc cash flow history.

Sign In Create Free Account

About Baudax Bio Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-065200

Figures are derived from filed reports and may be restated. Historical data is subject to revision.